切换至 "中华医学电子期刊资源库"
高级检索
中华肾病研究电子杂志

中华肾病研究电子杂志 ›› 2022, Vol. 11 ›› Issue (04) : 197 -201. doi: 10.3877/cma.j.issn.2095-3216.2022.04.003

论著

递增式血液透析对终末期肾病患者肾功能、微炎症及死亡率的影响
王婷燕1,†(), 申颖娇1, 王爱平1, 姚明凤1   
  1. 1. 046000　山西省长治市人民医院肾内科
  • 收稿日期:2022-03-24 出版日期:2022-08-28
  • 通信作者: 王婷燕

Effect of incremental hemodialysis on renal function, microinflammation and mortality in end-stage renal disease patients

Tingyan Wang1,†(), Yingjiao Shen1, Aiping Wang1, Mingfeng Yao1   

  1. 1. Department of Nephrology, Changzhi People′s Hospital, Changzhi 046000, Shanxi Province, China
  • Received:2022-03-24 Published:2022-08-28
  • Corresponding author: Tingyan Wang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

王婷燕, 申颖娇, 王爱平, 姚明凤. 递增式血液透析对终末期肾病患者肾功能、微炎症及死亡率的影响[J/OL]. 中华肾病研究电子杂志, 2022, 11(04): 197-201.

Tingyan Wang, Yingjiao Shen, Aiping Wang, Mingfeng Yao. Effect of incremental hemodialysis on renal function, microinflammation and mortality in end-stage renal disease patients[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(04): 197-201.

目的

研究递增式血液透析(IHD)对终末期肾病(ESRD)患者肾功能、微炎症及死亡率的影响。

方法

选取2017年7月至2021年6月于我院行血液透析(HD)治疗的ESRD患者84例，按照随机数字表法将84例ESRD患者分为递增组(n＝42)与常规组(n＝42)。治疗前及治疗6个月后，观察两组透析充分及生存情况、血尿素氮(BUN)、胱抑素C(CysC)、血清肌酐(Scr)、残余尿量(RUV)、尿素氮下降率(URR)、Kt/V等肾功能指标，血清C反应蛋白(CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和β2微球蛋白(β2-MG)等微炎症指标，以及透析期间不良反应。

结果

与常规组相比，递增组透析充分率增高，死亡率降低(P<0.05)。治疗6个月后，与常规组相比，递增组的BUN、CysC、Scr、RUV降低；URR、Kt/V增高(P<0.05)；血清CRP、IL-6、TNF-α及β2-MG水平降低(P<0.05)；不良反应发生率降低(P<0.05)。

结论

IHD可以保护ESRD患者的残余肾功能，抑制机体微炎症，降低不良反应率和死亡率。

关键词: 递增式血液透析, 终末期肾病, 肾功能, 微炎症, 死亡率
Objective

To investigate the effect of incremental hemodialysis (IHD) on renal function, microinflammation, and mortality in end-stage renal disease (ESRD) patients.

Methods

A total of 84 ESRD patients who received HD treatment in our hospital from July 2017 to June 2021 were selected. By means of the random number table method, the patients were divided into the incremental group (n=42) and the routine group (n=42). Before and 6 months after the treatment, the following indexes were observed, including dialysis adequacy, survival, BUN, cystatin C (CysC), serum creatinine (Scr), residual urine volume (RUV), urea nitrogen reduction rate (URR), Kt/V, C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and β2 microglobulin (β2-MG), as well as adverse reactions during dialysis.

Results

Compared with the routine group, the incremental group showed higher dialysis adequacy rate and lower mortality rate (P<0.05). After 6 months of the treatment, compared with the routine group, the incremental group displayed lower levels of BUN, CysC, Scr, and RUV (P<0.05), higher levels of URR and Kt/V (P<0.05), and lower levels of serum CRP, IL-6, TNF-α and β2-MG (P<0.05), as well as lower rate of adverse reactions (P<0.05).

Conclusion

IHD could protect the residual kidney function of ESRD patients, inhibit the body′s microinflammation, and reduce both the adverse reaction rate and mortality rate.

Key words: Incremental hemodialysis, End-stage renal disease, Renal function, Microinflammation, Mortality rate
表1 两组患者基线资料比较
基线资料 递增组(n＝42) 常规组(n＝42) χ2/t值 P值
性别(男/女) 22/20 24/18 0.190 0.663
年龄(岁) 61.23±6.42 61.31±6.48 0.057 0.955
疾病类型(慢性肾小球肾炎/糖尿病肾病/高血压肾病) 20/17/5 23/15/4 0.445 0.800
体重(kg) 58.09±6.15 58.52±6.21 0.319 0.751
收缩压(mmHg) 142.61±4.20 142.64±4.23 0.033 0.974
舒张压(mmHg) 87.28±5.09 87.31±5.12 0.027 0.979
血红蛋白(g/L) 80.38±8.31 80.43±8.35 0.028 0.978
白蛋白(g/L) 4.29±0.45 4.32±0.47 0.299 0.766
血磷(mmol/L) 1.86±0.20 1.83±0.18 0.723 0.472
血钙(mmol/L) 2.06±0.23 2.08±0.25 0.382 0.704
iPTH(μg/L) 243.07±27.23 247.75±27.26 0.787 0.434
空腹血糖(mmol/L) 15.67±1.92 15.63±1.89 0.096 0.924
餐后2 h血糖(mmol/L) 27.09±2.83 27.01±2.81 0.130 0.897
表2 两组透析充分及生存情况比较[例(%)]
指标 递增组(n＝42) 常规组(n＝42) χ2值 P值
透析充分 36(85.71) 28(66.67) 4.150 0.042
死亡 1(2.38) 8(19.05) － 0.029
表3 两组肾功能指标比较(±s)
指标 时间 递增组 常规组 t值　 P值
BUN(mmol/L) 治疗前 11.28±1.32 11.24±1.30 0.140 0.889
  治疗6个月后 7.19±0.74a 8.87±0.92a 8.409 <0.001
CysC(mg/L) 治疗前 2.98±0.31 2.96±0.30 0.301 0.765
  治疗6个月后 1.47±0.16a 1.78±0.19a 7.358 <0.001
Scr(μmol/L) 治疗前 99.87±10.23 98.95±10.20 0.413 0.681
  治疗6个月后 80.37±8.34a 88.74±9.11a 3.978 <0.001
URR(%) 治疗前 50.97±5.43 51.05±5.47 0.067 0.947
  治疗6个月后 71.07±7.34a 65.92±6.84a 3.327 0.001
Kt/V 治疗前 0.95±0.11 0.96±0.12 0.398 0.692
  治疗6个月后 1.42±0.16a 1.30±0.15a 3.546 0.001
RUV(ml) 治疗前 1649.07±171.29 1641.26±169.28 0.210 0.834
  治疗6个月后 379.98±40.32a 553.76±58.95 15.769 <0.001
表4 两组微炎症指标比较(±s)
指标 时间 递增组 常规组 t值　 P值
CRP(mg/L) 治疗前 10.84±1.23 10.81±1.21 0.113 0.911
  治疗6个月后 4.97±0.52a 5.86±0.61a 6.542 <0.001
IL-6(ng/L) 治疗前 8.43±0.87 8.39±0.86 0.212 0.833
  治疗6个月后 3.86±0.41a 4.58±0.48a 6.720 <0.001
TNF-α(μg/L) 治疗前 42.95±4.50 42.86±4.58 0.091 0.928
  治疗6个月后 26.11±2.82a 32.17±3.33a 8.186 <0.001
β2-MG(mg/mL) 治疗前 15.37±1.81 15.32±1.79 0.127 0.899
  治疗6个月后 8.57±0.93a 10.65±1.22a 8.035 <0.001
表5 两组不良反应比较[例(%)]
指标 递增组(n＝42) 常规组(n＝42) χ2值 P值
胃肠道反应 1(2.38) 1(2.38)    
营养不良 1(2.38) 3(7.14)    
低蛋白血症 1(2.38) 1(2.38)    
瘙痒 2(4.76) 3(7.14)    
心血管疾病 1(2.38) 5(11.90)    
贫血 1(2.38) 4(9.52)    
合计 7(16.67) 17(40.48) 3.833 0.016
[1]
Cobo G, Lindholm B, Stenvinkel P. Chronic inflammation in end-stage renal disease and dialysis [J]. Nephrol Dial Transplant, 2018, 33(Suppl 3): iii35-iii40.
[2]
Khan S, Rosner MH. Peritoneal dialysis for patients with end-stage renal disease and liver cirrhosis [J]. Perit Dial Int, 2018, 38(6): 397-401.
[3]
Davey CH, Webel AR, Sehgal AR, et al. Fatigue in individuals with end-stage renal disease [J]. Nephrol Nurs J, 2019, 46(5): 497-508.
[4]
Dhondup T, Qian Q. Electrolyte and acid-base disorders in chronic kidney disease and end-stage kidney failure [J]. Blood Purif, 2017, 43(1-3): 179-188.
[5]
Garofalo C, Borrelli S, De Stefano T, et al. Incremental dialysis in ESRD: systematic review and meta-analysis [J]. J Nephrol, 2019, 32(5): 823-836.
[6]
Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation [J]. Am J Kidney Dis, 2007, 50(2): 169-180.
[7]
Welles CC, Cervantes L. Hemodialysis care for undocumented immigrants with end-stage renal disease in the United States [J]. Curr Opin Nephrol Hypertens, 2019, 28(6): 615-620.
[8]
Chazot C, Jean G. End-stage kidney patients require hemodialysis therapy full start [J]. Blood Purif, 2019, 47(1-3): 214-222.
[9]
Tattersall J. Residual renal function in incremental dialysis [J]. Clin Kidney J, 2018, 11(6): 853-856.
[10]
Li T, Wilcox CS, Lipkowitz MS, et al. Rationale and strategies for preserving residual kidney function in dialysis patients [J]. Am J Nephrol, 2019, 50(6): 411-421.
[11]
Tangvoraphonkchai K, Davenport A. Increasing haemodialytic clearances as residual renal function declines: an incremental approach [J]. Blood Purif, 2017, 44(3): 217-226.
[12]
Soares E, Valério P, Abrantes C, et al. An unexpected cause of residual renal function loss [J]. Perit Dial Int, 2020, 40(4): 422-424.
[13]
Shen Q, Fang X, Zhai Y, et al. Risk factors for loss of residual renal function in children with end-stage renal disease undergoing automatic peritoneal dialysis [J]. Perit Dial Int, 2020, 40(4): 368-376.
[14]
Murea M, Moossavi S, Garneata L, et al. Narrative review of incremental hemodialysis [J]. Kidney Int Rep, 2019, 5(2): 135-148.
[15]
Murea M, Kalantar-Zadeh K. Incremental and twice-weekly hemodialysis program in practice [J]. Clin J Am Soc Nephrol, 2020, 16(1): 147-149.
[16]
Benackova K, Saudan P. Incremental hemodialysis "less is more" also when starting hemodialysis? [J]. Rev Med Suisse, 2020, 16(683): 395-398.
[17]
Hazara AM, Bhandari S. Can incremental haemodialysis reduce early mortality rates in patients starting maintenance haemodialysis? [J]. Curr Opin Nephrol Hypertens, 2019, 28(6): 641-647.
[18]
Basile C, Davenport A, Mitra S, et al. Frontiers in hemodialysis: innovations and technological advances [J]. Artif Organs, 2021, 45(2): 175-182.
[19]
Golper TA. Incremental dialysis: review of recent literature [J]. Curr Opin Nephrol Hypertens, 2017, 26(6): 543-547.
[20]
Maraj M, Kusnierz-Cabala B, Dumnicka P, et al. Malnutrition, inflammation, atherosclerosis syndrome (MIA) and diet recommendations among end-stage renal disease patients treated with maintenance hemodialysis [J]. Nutrients, 2018, 10(1): 69.
[21]
Casino FG, Basile C. A user-friendly tool for incremental haemodialysis prescription [J]. Nephrol Dial Transplant, 2018, 33(6): 1046-1053.
[1] 赵飞鸿, 陈颖杰, 林静芳, 郑晓春, 廖燕凌. 超声引导下周围神经阻滞对髋膝关节置换术后恢复的影响[J/OL]. 中华关节外科杂志(电子版), 2024, 18(04): 457-468.
[2] 中华医学会器官移植学分会, 中国医疗保健国际交流促进会肾脏移植学分会. 中国胰肾联合移植临床诊疗指南[J/OL]. 中华移植杂志(电子版), 2024, 18(03): 129-147.
[3] 王小琴, 汪丽, 崔建英. 无张力疝修补术治疗慢性肾功能衰竭合并腹股沟疝患者的疗效[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 538-542.
[4] 林科灿, 罗柳平. 肝胰十二指肠切除术在胆囊癌和胆管癌应用中的关键问题[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 774-778.
[5] 李佳莹, 王旭丹, 梁雪, 张雷, 李佳英. 1990~2021年中国结直肠癌死亡趋势分析[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 274-279.
[6] 杨明, 张金珠, 王锡山. 全国肿瘤登记中心发布的2013年至2022年结直肠癌流行数据趋势解读[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(03): 177-181.
[7] 张金珠, 杨明, 王锡山. 中国、美国及世界结直肠癌流行病学与疾病负担的对比和思考[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(02): 89-93.
[8] 陈意志. 核磁共振钆造影剂导致的肾源性系统性纤维化[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 358-358.
[9] 王小龙, 吴杰, 冯哲, 文浩, 段姝伟, 梁爽, 蔡广研. 心内科病房急性肾损伤且行肾脏替代治疗患者短期预后不良的危险因素分析[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 241-248.
[10] 刘思含, 张静. 老年人血清铁与C 反应蛋白的比值及25-羟基维生素D3 与肾功能受损的关系研究[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 268-272.
[11] 刘宇立, 姚瑶, 徐锦雯. 过敏性紫癜性肾炎患儿肾功能不全的影响因素分析[J/OL]. 中华肾病研究电子杂志, 2024, 13(02): 68-73.
[12] 张今宜, 李月红. 慢性肾脏病患者接种新型冠状病毒疫苗有效力及接种策略的研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(02): 97-100.
[13] 余海峰, 聂艳芳, 陈孜炜, 李春胜. 不同剂量火把花根片降低蛋白的尿疗效分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(02): 166-170.
[14] 李文哲, 王毅, 崔建, 郑启航, 王靖彦, 于湘友. 新疆维吾尔自治区重症患者急性肾功能异常的危险因素分析[J/OL]. 中华卫生应急电子杂志, 2024, 10(05): 269-276.
[15] 中国医师协会外科医师分会肥胖和代谢病外科专家工作组, 中国医师协会外科医师分会肥胖代谢外科综合管理专家工作组, 中国肥胖代谢外科研究协作组. 中国肥胖代谢外科数据库：2023年度报告[J/OL]. 中华肥胖与代谢病电子杂志, 2024, 10(02): 73-83.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号